Opinion|Videos|July 9, 2024
Balancing Safety and Efficacy: Optimizing Topical Treatment Options for AD
Casey Butrus, PharmD; Michael Cameron, MD, FAAD, and Brittany Craiglow, MD, provide insights on the differences between therapies that require continuous use versus those that can be intermittently used for atopic dermatitis (AD), explore the potential of combination therapy, and discuss optimal efficacy and duration of therapy regimens to maximize patient outcomes.
Advertisement
- When it comes to topical ruxolitinib, how do you balance the efficacy versus the safety when deciding to treat patients with it?
- How do treatment options differ in terms of administration schedule (continuous versus non-continuous), and how does the need for breakthrough topical steroids influence your decision on therapy options?
- In the managed care space, what is the role of combination therapy in AD and what restrictions might be considered?
- From a payer’s perspective, how do you take into account when a product does not need continuous use and still be efficacious, potentially allowing for time off therapy?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Related Articles
- BCMA-Targeted Bispecific Antibodies: Navigating the New Frontier of Myeloma
September 17th 2025
- Linvoseltamab: A New Horizon for Relapsed Myeloma
September 17th 2025
- Rapid Therapeutic Effects Seen With a JAK Inhibitor
September 17th 2025
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
Cumulative Atropine Not Associated With Increased Risk of Ocular Events in Children With Myopia
2
West Coast Health Alliance Releases First Vaccine Guidelines, Aiming to Replace CDC Recommendations
3
Hospitals in Underserved Communities Less Likely to Adopt Health Information Technology
4
Sotatercept Shows Right Heart Gains in PAH: Anjali Vaidya, MD
5